| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 12/19/2023, p1868-1868, 1p |
| Abstrakt: |
A recent study conducted by researchers at Northwestern University highlights the need for comprehensive molecular testing in patients with uncommon driver mutations. The study focused on a patient with RET fusion-driven non-small cell lung cancer (NSCLC) who developed resistance to selective RET inhibitors. The patient was initially treated with chemotherapy and immune therapy, then switched to selpercatinib, and eventually had fam-trastuzumab deruxtecan added to their treatment. The case demonstrates the importance of identifying unexpected resistance mechanisms and underscores the need for thorough molecular testing at both diagnosis and progression. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
